Digitisation | November 14, 2023
BioPhy launches AI platform to accelerate the drug development market
The company has raised US$4.5 million in funding for its AI operating system
The company has raised US$4.5 million in funding for its AI operating system
European operations' revenue grew 58.4% to Rs 599.7 crore
The companies plan to start a pivotal Phase 3 trial in the coming months
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
PFA technology is only marketed in Europe, and yet, it has been dominating the electrophysiology market by storm
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Lokavant provides clinical trial intelligence
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Subscribe To Our Newsletter & Stay Updated
